Naomi V completed this course and earned a Pharmuni certificate.
Introduction to Pharmacovigilance
ISO 9001
Quality Management System
Certificate Registration No.: 12 100 60610 TMS
About the Introduction to Pharmacovigilance
Pharmacovigilance plays a critical role in protecting patient safety throughout the lifecycle of medicinal products. This course provides a structured introduction to the principles, regulatory framework, and operational processes that underpin pharmacovigilance activities in the pharmaceutical industry.
You will gain a clear understanding of how adverse events are identified, reported, evaluated, and monitored, as well as how pharmacovigilance systems support ongoing benefit–risk assessment and regulatory compliance.
The course focuses on key pharmacovigilance concepts in practice, including:
• The purpose and regulatory basis of pharmacovigilance
• Adverse event reporting and case processing principles
• Roles and responsibilities within a pharmacovigilance system
• Ongoing safety monitoring and benefit–risk evaluation
Through structured explanations and practical examples, this course helps learners understand how pharmacovigilance activities contribute to patient safety and regulatory oversight. It is best suited to professionals who require a foundational understanding of pharmacovigilance processes within regulated environments.
This foundational course introduces the principles and practices that underpin PV systems worldwide. You will explore how regulatory authorities such as the EMA, FDA, ICH, and WHO shape global PV expectations, and how each company must integrate these requirements into its Quality Management System (QMS).
Learning Objective 1
Explain the purpose and scope of Pharmacovigilance (PV) in maintaining patient safety and regulatory compliance under EMA, FDA, and ICH frameworks.
Learning Objective 2
Classify safety information by distinguishing between Adverse Events (AEs), Adverse Drug Reactions (ADRs), and Product Quality Complaints.
Learning Objective 3
Identify primary pharmacovigilance data sources including EudraVigilance, spontaneous reports, and medical literature, and describe how each contributes to safety monitoring.
Learning Objective 4
Describe how pharmacovigilance activities fit within the broader pharmaceutical quality system and contribute to regulatory inspection readiness.
Learning Objective 5
Outline the core responsibilities and structure of a Pharmacovigilance Department and its collaboration with Regulatory Affairs, Quality Assurance, and Medical Information functions.
Learning Objective 6
Demonstrate correct adverse-event reporting principles, including timelines, documentation requirements, and data-protection obligations.
Learning Objective 7
Evaluate professional behaviours that support a culture of pharmacovigilance compliance, including ethical communication and prompt reporting of safety information.